Saffron

Metadata

Approved Indications

Commission E (Germany)

• No monograph exists. Saffron was not part of the traditional German or Central European phytotherapy pharmacopeia during the Commission E evaluation period (1978-1994). Its medicinal use is rooted primarily in Persian, Ayurvedic, and Arabic traditions rather than the European herbal medicine tradition assessed by Commission E.

ESCOP (European Scientific Cooperative on Phytotherapy)

• No monograph exists. ESCOP has not assessed saffron for any indication. The herb falls outside the scope of the European phytotherapy tradition that ESCOP systematically evaluates.

EMA/HMPC (European Medicines Agency)

• No monograph exists. The EMA Committee on Herbal Medicinal Products (HMPC) has not published an assessment report, community monograph, or community list entry for Crocus sativus. This means saffron has no formal EU regulatory pathway as either a “well-established use” or “traditional use” herbal medicinal product.

Why No European Monographs Despite Strong RCT Evidence?

The absence of European monographs for saffron is notable given its relatively robust clinical evidence base — arguably stronger than several herbs that do hold monographs. Several factors explain this gap:

1. Cultural origin: Saffron’s therapeutic tradition is Persian, Ayurvedic, and Arabic. The European monograph system was built around Central and Western European herbal traditions. Herbs from non-European traditions (Bacopa, Ashwagandha, Saffron) typically lack this regulatory recognition regardless of their evidence quality.

2. No commercial sponsor in the EU: European herbal monographs are often driven by pharmaceutical companies that manufacture standardized products (e.g., Schwabe for Silexan/lavender). Saffron lacks a dominant European manufacturer with regulatory ambitions. The most prominent standardized extract (affron by Pharmactive, a Spanish company) is marketed primarily as a food supplement rather than a herbal medicinal product.

3. Relatively recent clinical research: The pivotal RCTs for saffron began in 2004-2005, and the body of evidence has grown primarily in the past two decades. The regulatory assessment process lags behind the published literature.

4. Geographic concentration of research: Most clinical trials have been conducted in Iran, which may reduce perceived generalizability in European regulatory assessment, despite the high methodological quality of many of these trials.

Other Regulatory Recognition

• Ayurvedic Pharmacopoeia of India: Saffron (Kumkuma/Kesar) is an official drug with traditional indications including Rasayana (rejuvenation), mood support, complexion enhancement, and menstrual regulation.
• Iranian Pharmacopoeia: Listed as a traditional medicine with multiple indications.
• United States: Available as a dietary supplement under DSHEA. The standardized extract affron has received New Dietary Ingredient (NDI) notification acceptance from the FDA.
• Australian TGA: Saffron is listed as a permitted herbal substance in complementary medicines.

Agreement/Disagreement

The complete absence of European regulatory recognition for saffron contrasts sharply with its clinical evidence profile. Saffron has more positive RCTs for depression than several European-tradition herbs that hold formal monographs. This discrepancy highlights a systemic bias in the European monograph system toward herbs with European cultural heritage, rather than a negative scientific assessment of saffron’s efficacy.

Conditions Treated

Primary (Strong Evidence) — Depression

Mild-to-moderate major depressive disorder is saffron’s best-studied indication, with the most extensive clinical trial evidence.

• Multiple RCTs (>12 trials) have demonstrated that saffron extract (30 mg/day) significantly reduces depressive symptoms compared to placebo, with effect sizes comparable to first-line antidepressants.
• Head-to-head active comparator trials show equivalence to fluoxetine (20 mg/day), imipramine (100 mg/day), and citalopram (40 mg/day) for HAM-D score reduction over 6-8 weeks.
• Meta-analyses confirm a large effect size versus placebo (overall effect size = -4.26, 95% CI: -5.76 to -2.77) and non-inferiority to conventional antidepressants.
• Both the stigma and the petal of Crocus sativus have demonstrated antidepressant activity in clinical trials, though the stigma is more extensively studied.
• A 2025 RCT in medical students with mild-to-moderate depression showed significant improvements in both depression severity and cortisol levels. [Source: Helvian et al. 2025, Pharmacognosy Magazine]
• The proprietary extract affron (28 mg/day) has shown efficacy in adults with subclinical depressive symptoms in the largest trial to date (n > 200). [Source: Journal of Nutrition, 2025]

Evidence quality assessment: The depression evidence is strong in terms of consistency and effect size but limited by relatively small individual trial sizes (typically n = 30-66), short durations (typically 6-8 weeks), and geographic concentration of research in Iran. The 2024-2025 expansion of research to non-Iranian populations and use of standardized extracts like affron strengthens the evidence base considerably.

Secondary (Moderate Evidence)

Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD)

• Agha-Hosseini et al. (2008) conducted a landmark DBRPCT showing that saffron 30 mg/day reduced PMS symptoms significantly more than placebo, with 76% of the saffron group experiencing a 50% or greater reduction in PMS symptom severity versus only 8% in the placebo group. [Source: PubMed 18271889]
• Rajabi et al. (2021) demonstrated saffron’s efficacy in PMDD, with results comparable to fluoxetine but with significantly fewer adverse effects. [Source: PMC7792881]
• A 2025 systematic review and meta-analysis confirmed saffron’s positive effect on PMS symptoms across doses of 14-60 mg/day. [Source: PubMed 41151539]

Anxiety

• A systematic review and meta-analysis (Toth et al., 2019) found a large positive effect size for saffron versus placebo for anxiety symptoms (g = 0.95, P < 0.006). [Source: PubMed 31135916]
• Mazidi et al. studied saffron as add-on therapy to sertraline in mild-to-moderate GAD (n = 40), finding significantly lower Hamilton Anxiety Rating Scale scores at 6 weeks in the saffron group versus placebo (2.95 vs. 5.05; p = 0.005). [Source: Avicenna Journal of Neuro-Psycho-Pharmacology]
• A 2024 meta-analysis comparing saffron to SSRIs for anxiety found nonsignificant differences in efficacy, with saffron producing fewer adverse events. [Source: PubMed 38913392]

SSRI-Induced Sexual Dysfunction

• In men: Modabbernia et al. (2012) conducted a DBRPCT in 36 men with fluoxetine-induced sexual dysfunction. Saffron 30 mg/day for 4 weeks significantly improved erectile function and intercourse satisfaction compared to placebo on the International Index of Erectile Function (IIEF). [Source: PubMed 22552758]
• In women: Kashani et al. (2013) demonstrated in a DBRPCT (n = 34) that saffron 30 mg/day significantly improved arousal, lubrication, and pain scores on the Female Sexual Function Index (FSFI) in women with fluoxetine-induced sexual dysfunction. [Source: PubMed 23280545]
• Meta-analysis: Maleki-Saghooni et al. (2019) conducted a systematic review and meta-analysis of 5 studies (n = 173), finding a statistically significant overall positive effect of saffron on sexual dysfunction, with significant improvements in arousal, lubrication, and pain, though not in desire, satisfaction, or orgasm. [Source: PMC6727438]
• This application is clinically relevant because sexual dysfunction is one of the most common reasons for SSRI discontinuation, and saffron offers a complementary approach without pharmacokinetic drug interactions.

Traditional Use

Ayurvedic Medicine (Kesar/Kumkuma)

Saffron has been used in Ayurveda for over two millennia. It appears in the Charaka Samhita (circa 2nd century CE), where it is praised for sharpening the indriyas (senses) and purifying rasa dhatu (plasma tissue). Key traditional applications include:

• Rasayana (rejuvenation): Classified as a premier rejuvenating herb that supports ojas (vital essence) and promotes longevity.
• Mood and emotional balance: Traditionally prescribed for vishada (depression), chinta (excessive worry), and emotional dullness. Administered in warm milk (Kesar Doodh) as a daily tonic.
• Complexion enhancement: One of the most celebrated Ayurvedic herbs for skin radiance (varnya); applied topically and taken internally.
• Reproductive health: Used for menstrual irregularity, uterine tonic effects, and as a fertility-supporting herb. Traditionally given to pregnant women in very small doses (a few strands in milk) to support complexion of the child — though high-dose use in pregnancy is contraindicated.
• Respiratory health: Included in formulations like Sitopaladi Churna for reducing kapha in the lungs.
• Dosha effects: Balances all three doshas (tridoshahara), particularly vata and pitta. Its ushna virya (hot potency) and madhura vipaka (sweet post-digestive effect) make it versatile across constitutional types.

Persian (Unani/Traditional Iranian) Medicine

Saffron (Za’faran) holds a central place in traditional Persian medicine, where it has been used for over 3,000 years:

• Temperament classification: Classified as hot and dry in the second degree in Unani pharmacology.
• Mood disorders: Used for melancholia (malikhuliya) and sadness — a traditional use that aligns remarkably well with the modern clinical evidence for depression.
• Cardiovascular tonic: Prescribed as a heart-strengthening agent (muqawwi-e qalb).
• Digestive support: Used for appetite stimulation and as a carminative.
• Respiratory conditions: Employed in decoctions for chronic bronchitis and cough.
• External use: Applied as a paste for headache, skin conditions, and joint inflammation.

Traditional Chinese Medicine

While not a primary TCM herb, saffron (Xi Hong Hua or Fan Hong Hua) has been incorporated into TCM practice, primarily for:

• Invigorating blood circulation and removing blood stasis
• Calming the spirit (an shen) for insomnia and anxiety
• Cooling the blood in febrile conditions

Mechanism of Action

Saffron’s antidepressant and psychotropic effects arise from a multi-target pharmacological profile. Unlike conventional antidepressants that typically target a single neurotransmitter system, saffron’s bioactive compounds modulate multiple pathways simultaneously, which may account for its broad-spectrum mood effects with relatively mild side effects.

Active Compounds and Their Roles

Primary Mechanisms

1. Serotonin Reuptake Inhibition

Saffron extract and its constituent crocin inhibit the serotonin transporter (SERT), increasing the availability of serotonin (5-HT) in the synaptic cleft. This mechanism is directly analogous to the mechanism of SSRIs (fluoxetine, citalopram, sertraline) and is the most clinically validated of saffron’s antidepressant mechanisms. The potency of serotonin reuptake inhibition by saffron is lower than that of pharmaceutical SSRIs, but the clinical equivalence observed in head-to-head trials suggests that saffron’s multi-target activity compensates for any single-target potency deficit. [Source: Hausenblas et al. 2013; Lopresti & Drummond 2014]

2. Monoamine Oxidase (MAO) Inhibition

Crocin acts as a non-competitive inhibitor of both MAO-A and MAO-B in the micromolar range, binding to allosteric sites on the enzyme rather than the catalytic active site. MAO-A inhibition increases synaptic levels of serotonin and norepinephrine, while MAO-B inhibition preserves dopamine levels. Importantly, safranal is inactive toward both MAO isoforms — the MAO inhibitory activity is specific to the crocin/crocetin compounds. The non-competitive, allosteric nature of this inhibition may reduce the risk of the tyramine (“cheese”) reaction that limits classical MAO inhibitor antidepressants. [Source: Ricciardelli et al. 2022, Molecules 27:2076]

3. NMDA Receptor Antagonism and Glutamate Modulation

Saffron extract and trans-crocetin demonstrate antagonistic effects on NMDA receptors in rat cortical brain slices, decreasing glutamate-induced membrane depolarization and inhibiting glutamatergic synaptic transmission. Crocetin specifically binds to the phencyclidine (PCP)-binding site of the NMDA receptor and also shows affinity for the sigma-1 receptor. The NMDA antagonist mechanism is relevant because excessive glutamatergic signaling is implicated in depression pathophysiology, and ketamine (another NMDA antagonist) has shown rapid antidepressant effects. Notably, the saffron whole extract was also active on kainate receptors, while trans-crocetin alone was not, suggesting synergistic effects among saffron’s multiple constituents. [Source: Berger et al. 2011, PubMed 21352900; Lechtenberg et al. 2008]

4. BDNF Upregulation and Neuroplasticity

Saffron and crocin upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus, a key mechanism shared with conventional antidepressants and exercise. Crocin activates the PACAP/ERK/CREB signaling cascade, which enhances synaptic plasticity and promotes neuronal survival. In animal models, saffron carotenoids reversed unpredictable chronic mild stress (UCMS)-induced decreases in hippocampal BDNF and phosphorylated CREB, while also normalizing NR2B (NMDA receptor subunit) signaling. This neuroplasticity mechanism may explain both the antidepressant effects and the emerging evidence for cognitive benefits. [Source: Ghasemi et al. 2024, Phytomedicine; Vahdati Hassani et al. 2014]

Secondary Mechanisms

5. Dopamine Modulation

Saffron promotes dopamine release and modulates dopaminergic neurotransmission, which is associated with pleasure, motivation, and reward processing. This mechanism is particularly relevant to the anhedonia (inability to experience pleasure) component of depression, which is poorly addressed by SSRIs alone. A 2025 preclinical and human study specifically examined saffron’s antianhedonic effects. [Source: PMC7397008]

6. Anti-Inflammatory and Antioxidant Effects

Crocin and crocetin are potent antioxidants that scavenge reactive oxygen species and reduce lipid peroxidation. Saffron also inhibits NF-kB signaling and reduces pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Given the neuroinflammatory hypothesis of depression — which posits that chronic low-grade inflammation contributes to depressive pathology — these anti-inflammatory properties may contribute to saffron’s antidepressant efficacy. [Source: Lopresti & Drummond 2014]

7. HPA Axis Modulation

A 2025 RCT demonstrated that saffron supplementation significantly reduced cortisol levels in medical students with mild-to-moderate depression, suggesting modulation of the hypothalamic-pituitary-adrenal (HPA) axis stress response. HPA axis dysregulation (elevated cortisol) is a consistent finding in major depression. [Source: Helvian et al. 2025]

8. GABAergic Activity (Safranal)

Safranal, the aromatic compound responsible for saffron’s distinctive scent, has demonstrated anxiolytic and sedative properties through interaction with GABA-A receptors. This mechanism is distinct from the serotonergic actions of crocin and may contribute to the anxiolytic effects observed in clinical trials.

Pharmacological Profile Summary

This multi-target profile is a distinguishing feature of saffron compared to conventional single-target antidepressants and may explain why clinical equivalence is achieved despite lower potency at any single molecular target.

Clinical Evidence Summary

Meta-Analyses

Key Head-to-Head Comparator Trials

Saffron vs. Placebo

Akhondzadeh et al. (2005) — Landmark Placebo-Controlled Trial

• Design: Double-blind, randomized, placebo-controlled, 6 weeks
• n = 40 outpatients with mild-to-moderate depression (DSM-IV major depression, HAM-D >= 18)
• Intervention: Saffron stigma 30 mg/day (15 mg BID) vs. placebo
• Result: Saffron produced a significantly greater reduction in HAM-D scores than placebo at week 6 (P < 0.001). The remission rate was significantly higher with saffron.
• Significance: First rigorous placebo-controlled demonstration of saffron’s antidepressant effect.
• [Source: PubMed 15852492]

Saffron vs. Fluoxetine

Akhondzadeh et al. (2007) — Petal vs. Fluoxetine

• Design: Pilot double-blind, randomized, active-controlled, 8 weeks
• n = 40 outpatients with mild-to-moderate depression
• Intervention: Crocus sativus petal 30 mg/day vs. fluoxetine 20 mg/day
• Result: No significant difference between groups in HAM-D score reduction at 8 weeks. Saffron petal was equivalent to fluoxetine with fewer reported side effects.
• Significance: Demonstrated that even the petal (not just the stigma) has antidepressant activity comparable to a first-line SSRI.
• [Source: Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):439-442]

Noorbala et al. (2005) — Stigma vs. Fluoxetine

• Design: Double-blind, randomized, active-controlled, 6 weeks
• n = 40 outpatients with mild-to-moderate depression
• Intervention: Saffron stigma 30 mg/day vs. fluoxetine 20 mg/day
• Result: No significant difference in HAM-D score improvement between groups (P = 0.71). Both groups showed clinically meaningful improvement.
• [Source: J Ethnopharmacol 2005;97(2):281-284]

Tabeshpour et al. (2017) — Postpartum Depression

• Design: Double-blind, randomized, active-controlled, 6 weeks
• n = 60 women with mild-to-moderate postpartum depression
• Intervention: Saffron 30 mg/day vs. fluoxetine 20 mg/day
• Result: No significant difference between groups. Saffron was comparable to fluoxetine for postpartum depression with a better side effect profile (particularly relevant for breastfeeding considerations, though saffron’s safety in lactation is not established).
• [Source: PubMed 27595298]

Saffron vs. Imipramine

Akhondzadeh et al. (2004) — Stigma vs. Imipramine

• Design: Pilot double-blind, randomized, active-controlled, 6 weeks
• n = 30 outpatients with mild-to-moderate depression
• Intervention: Saffron stigma 30 mg/day vs. imipramine 100 mg/day
• Result: No significant difference in HAM-D scores between groups (P = 0.09). Saffron was equivalent to imipramine with markedly fewer anticholinergic side effects (dry mouth, sedation, constipation).
• Significance: Demonstrated equivalence to a tricyclic antidepressant, broadening the comparator base beyond SSRIs.
• [Source: PubMed 15341662]

Saffron vs. Citalopram

Ghajar et al. (2017) — Saffron vs. Citalopram for MDD with Anxious Distress

• Design: Double-blind, randomized, active-controlled, 6 weeks
• n = 66 patients with major depressive disorder and concurrent anxiety
• Intervention: Saffron 30 mg/day vs. citalopram 40 mg/day
• Result: Saffron had anxiolytic effects comparable to citalopram, with no severe adverse effects reported.
• [Source: J Affect Disord 2017;207:56-63]

Adjunctive Therapy Trials

Several trials have examined saffron as add-on therapy to conventional antidepressants:

• Saffron + sertraline for GAD: Significant additional benefit on Hamilton Anxiety Rating Scale scores when saffron 450 mg/day was added to sertraline compared to placebo add-on (p = 0.005). [Source: Avicenna J Neuropsychopharmacol]
• Saffron + SSRI for depression: Combination therapy showed enhanced response rates compared to SSRI alone in a small pilot study, suggesting potential augmentation benefit.

Standardized Extract Trials (affron)

The patented affron extract (standardized to >= 3.5% Lepticrosalides) has been studied in several recent clinical trials:

• Kell et al. (2017): DBRPCT, n = 128 healthy adults with self-reported low mood. affron 28 mg/day for 4 weeks significantly improved mood and reduced anxiety compared to placebo. [Source: Complement Ther Med 2017;33:58-64]
• Lopresti et al. (2020): Examined affron for sleep quality in adults with poor sleep, finding significant improvements, likely mediated through anxiolytic effects. [Source: J Clin Sleep Med]
• 2025 Large-Scale Trial: The most extensive affron trial to date (n > 200) demonstrated significant improvements in mood and emotional wellbeing in adults with subclinical depressive symptoms at 28 mg/day over 12 weeks. [Source: Journal of Nutrition 2025]

Evidence Limitations

1. Small sample sizes: Most individual trials enrolled 30-66 participants. While the consistency across trials is reassuring, no single trial provides definitive evidence.
2. Geographic concentration: The majority of pivotal RCTs were conducted in Iran by a relatively small number of research groups. Independent replication from diverse geographic settings is ongoing but still limited.
3. Short duration: Most trials ran for 6-8 weeks. Long-term efficacy and safety data beyond 6 months are scarce.
4. Severity range: Evidence is strongest for mild-to-moderate depression. Saffron has not been adequately studied for severe or treatment-resistant depression and should not be considered a substitute for conventional treatment in these populations.
5. Publication bias: A disproportionate number of positive trials may reflect publication bias, though meta-analyses have not identified strong evidence of this.
6. Heterogeneous preparations: Trials have used different saffron preparations (stigma, petal, crocin isolate, various extracts) at different standardizations, making cross-trial comparison imperfect.

Safety Profile

General Assessment

Saffron is generally well-tolerated at therapeutic doses (30 mg/day of extract) in clinical trials lasting up to 26 weeks. It has a long history of culinary use worldwide (as a spice in food) and millennia of traditional medicinal use. The therapeutic window is wide: culinary doses (a few milligrams) are far below the toxic threshold, and clinical doses (15-30 mg/day of extract) are well within established safety margins.

Contraindications

• Pregnancy (high doses): Saffron in amounts exceeding normal culinary use (generally considered > 5 g of raw saffron) has documented uterine stimulant and abortifacient effects. Traditional Ayurvedic use includes very small doses (1-2 strands) in pregnancy milk, but supplemental/extract doses are contraindicated. The uterotonic effect is dose-dependent, and typical therapeutic doses (30 mg extract, equivalent to much less than 5 g of raw spice) have not been shown to cause uterine effects, but the precautionary principle applies.
• Bipolar disorder: Saffron’s serotonergic and dopaminergic activity carries a theoretical risk of triggering manic or hypomanic episodes, similar to the risk posed by conventional antidepressants. No specific case reports have been documented, but caution is warranted and saffron should not be used as monotherapy in patients with known bipolar disorder.
• Bleeding disorders: Saffron may have antiplatelet effects and could theoretically increase bleeding risk in patients with bleeding disorders or on anticoagulant therapy. This is based primarily on in vitro and animal data. [UNCERTAIN — clinical significance not established]
• Hypotension: High-dose saffron (400 mg/day in the Modaghegh 2008 safety study) significantly decreased standing systolic blood pressure and mean arterial pressure. Patients with existing hypotension or on antihypertensive medications should be monitored. [Source: PubMed 18693099]

Drug Interactions

Saffron’s drug interaction profile is relatively favorable compared to St. John’s Wort (which has extensive CYP450 interactions), but several theoretical and emerging interactions warrant attention:

Important note: Unlike St. John’s Wort, saffron has not been shown to significantly induce or inhibit CYP450 enzymes in clinically meaningful ways. This means saffron is less likely to cause pharmacokinetic drug interactions that alter blood levels of co-administered medications — a significant practical advantage over St. John’s Wort for patients who require both an herbal antidepressant and other medications.

Side Effects

At therapeutic doses (15-30 mg/day of extract), saffron’s side effect profile is mild and typically comparable to placebo:

• Common (1-10%): Nausea, decreased appetite, headache, dry mouth, drowsiness (mild)
• Uncommon (<1%): Dizziness, constipation, vomiting, anxiety (paradoxical)
• Rare: Allergic reactions including rhinoconjunctivitis (occupational exposure primarily), bronchial asthma (in saffron workers), cutaneous pruritus, and anaphylaxis (case reports exist but are very rare)
• At supratherapeutic doses (>200 mg/day of raw saffron): More pronounced GI symptoms, numbness, tingling, yellowing of skin and mucous membranes (due to crocin pigment), bleeding (menstrual irregularity)

In the Modaghegh et al. (2008) safety evaluation in healthy volunteers:

• 200 mg and 400 mg/day of saffron tablets for 7 days caused slight decreases in red blood cells, hemoglobin, hematocrit, and platelets, and slight increases in sodium, BUN, and creatinine — all within normal clinical ranges and not clinically significant. [Source: PubMed 18693099]

Comparison to SSRIs: In the 2024 meta-analysis by Siddiqui et al., participants receiving saffron had significantly fewer adverse events than the SSRI group (risk difference: -0.06, 95% CI: -0.09 to -0.04). The most notable advantages of saffron over SSRIs include absence of sexual dysfunction (saffron actually improves sexual function), minimal GI disturbance, no weight gain, and no discontinuation syndrome.

Toxicology

• Lethal dose (LD50): Approximately 20 g of raw saffron in humans has been reported as potentially lethal, though this figure is based on historical reports. The LD50 in mice (intraperitoneal) is approximately 1.6 g/kg for aqueous extract.
• Toxic dose: Doses of 5 g or more of raw saffron stigma can cause serious adverse effects including vomiting, bloody diarrhea, hematuria, uterine bleeding, and organ failure. This is approximately 150-fold higher than the typical therapeutic extract dose.
• Therapeutic margin: The margin between the therapeutic dose (30 mg extract/day) and the toxic threshold (5 g raw stigma) provides a very wide safety window.
• Subchronic toxicity: No significant organ toxicity has been observed in clinical trials of up to 26 weeks’ duration at doses up to 100 mg/day of extract.
• Genotoxicity/mutagenicity: No evidence of genotoxic or mutagenic effects at therapeutic doses. Crocin and crocetin have actually demonstrated antimutagenic properties in some assays.

Pregnancy and Lactation

• Pregnancy: Category C. Saffron in large doses (well above culinary amounts) has documented uterine stimulant and abortifacient properties. Traditional Ayurvedic practice uses very small amounts (1-2 threads) in pregnancy, but supplemental doses are not recommended. No adequate human reproductive safety studies have been conducted for saffron extracts. Animal studies suggest potential teratogenicity at high doses. Avoid therapeutic doses during pregnancy.
• Lactation: Insufficient data. Not recommended at therapeutic doses. Culinary amounts are likely safe based on historical use.
• Fertility: Animal studies suggest saffron may have positive effects on sperm quality and motility, but human data are limited.

Clinical Dosage

Standardized Extract (Depression — Most Studied)

Dosing for Other Indications

Traditional Preparations

Key Dosing Considerations

1. Onset of action: Antidepressant effects in clinical trials are typically measurable within 2-3 weeks, with full effect at 6-8 weeks. This onset is comparable to SSRIs.
2. Do not exceed 1.5 g/day of raw saffron. Doses of 5 g or above may cause toxicity.
3. Quality matters: Saffron is the world’s most expensive spice by weight and is frequently adulterated. Clinical-grade standardized extracts (affron, or extracts standardized to crocin/safranal content) are preferred over raw saffron for therapeutic use.
4. Adulteration risk: Common adulterants include safflower (Carthamus tinctorius), turmeric (Curcuma longa), and artificial dyes. This makes standardized, third-party tested extracts critical for therapeutic applications.
5. Timing: Can be taken with or without food. Divided dosing (BID) is used in most clinical trials but once-daily dosing has not been specifically shown to be inferior.

Sources

Meta-Analyses and Systematic Reviews

• Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383. PubMed 24299602
• Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517-527. PMC4643654
• Toth B, Hegyi P, Lantos T, et al. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Med. 2019;85(1):24-31. PubMed 31135916
• Khaksarian M, Behzadifar M, Behzadifar M, et al. The efficacy of Crocus sativus (saffron) versus placebo and fluoxetine in treating depression: a systematic review and meta-analysis. Psychol Res Behav Manag. 2019;12:297-305. PMC6503633
• Siddiqui SA, et al. Effect of saffron versus selective serotonin reuptake inhibitors (SSRIs) in treatment of depression and anxiety: a meta-analysis of randomized controlled trials. Phytother Res. 2024. PubMed 38913392
• Maleki-Saghooni N, Mirzaeii K, Hosseinzadeh H, et al. Effects of saffron (Crocus sativus) on sexual dysfunction among men and women: a systematic review and meta-analysis. J Sex Marital Ther. 2019;45(6):507-521. PMC6727438

Key Randomized Controlled Trials — Depression

• Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complement Altern Med. 2004;4:12. PubMed 15341662
• Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148-151. PubMed 15852492
• Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284
• Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439-442
• Tabeshpour J, Sobhani F, Sadjadi SA, et al. A double-blind, randomized, placebo-controlled trial of saffron stigma (Crocus sativus L.) in mothers suffering from mild-to-moderate postpartum depression. Phytomedicine. 2017;36:145-152. PubMed 27595298
• Helvian FA, Syamsuddin S, Limoa E, et al. Saffron effectiveness to alleviate depression symptoms and cortisol level of medical students with mild-moderate depression: a randomized controlled trial. Pharmacognosy Magazine. 2025. doi:10.1177/0976500X251399510

Key RCTs — PMS/PMDD

• Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008;115(4):515-519. PubMed 18271889
• Rajabi F, Rahimi M, Ghaderi A, et al. Saffron for the management of premenstrual dysphoric disorder: a randomized controlled trial. Arch Womens Ment Health. 2021;24(2):323-333. PMC7792881

Key RCTs — Sexual Dysfunction

• Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology (Berl). 2012;222(3):381-388. PubMed 22552758
• Kashani L, Raisi F, Seirafi M, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54-60. PubMed 23280545

Mechanism of Action Studies

• Berger F, Hensel A, Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Neuroscience. 2011;180:238-247. PubMed 21352900
• Lechtenberg M, Schepmann D, Nieber K, Ghasemi T, Wunsch B, Imming P. Quality and functionality of saffron: quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and sigma-1 receptors. Planta Med. 2008;74(7):764-772
• Ricciardelli D, et al. Anti-depressant properties of crocin molecules in saffron. Molecules. 2022;27(7):2076. PMC9000812
• Ghasemi T, et al. Saffron carotenoids reversed the UCMS-induced depression and anxiety in rats: behavioral and biochemical parameters, and hippocampal BDNF/ERK/CREB and NR2B signaling markers. Phytomedicine. 2024

Safety Studies

• Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine. 2008;15(12):1032-1037. PubMed 18693099
• Hosseinzadeh H, Nassiri-Asl M. Avicenna’s (Ibn Sina) the Canon of Medicine and saffron (Crocus sativus): a review. Phytother Res. 2013;27(4):475-483

Standardized Extract Studies

• Kell G, Rao A, Beccaria G, Clayton P, Inarejos-Garcia AM, Prodanov M. affron a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58-64
• Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021;86:7-18

Connections

• St. John’s Wort: The most extensively studied herbal antidepressant. Both herbs have A/B-level evidence for mild-to-moderate depression, but St. John’s Wort has a major disadvantage in its extensive CYP450-mediated drug interactions (particularly CYP3A4 induction). Saffron may be a better choice for patients taking other medications. St. John’s Wort has European monographs (Commission E, ESCOP, EMA) while saffron does not.
• Lavender (Silexan): Both target mood disorders but with different primary indications — lavender for anxiety (GAD), saffron for depression. Their mechanisms are distinct (lavender: VGCC inhibition; saffron: serotonergic/multi-target). Could theoretically be complementary for comorbid depression and anxiety, though no combination trials exist.
• Rhodiola: Shares some mechanistic overlap (monoamine modulation, BDNF effects, HPA axis modulation). Rhodiola is better studied for stress-related fatigue and has an EMA/HMPC monograph, while saffron has stronger depression-specific evidence. Both lack CYP450 concerns to the degree seen with St. John’s Wort, though rhodiola has moderate CYP3A4 and CYP2C9 inhibition.
• Lemon Balm: Both have anxiolytic properties and traditional use for mood. Lemon Balm has weaker depression-specific evidence but stronger European regulatory recognition. Could be considered for milder mood disturbances where the full antidepressant profile of saffron is not needed.
• Bacopa: Shares the characteristic of being a well-studied Ayurvedic herb lacking European monographs. Both upregulate BDNF and modulate serotonergic pathways, but Bacopa targets cognition while saffron targets mood. The two could theoretically complement each other for patients with depression-related cognitive impairment.
• General note on regulatory asymmetry: Saffron, Bacopa, and Ashwagandha represent a group of Ayurvedic herbs with strong clinical evidence bases that are systematically underrepresented in European phytotherapy regulation, despite evidence quality that meets or exceeds many European-tradition herbs with formal monographs.